Recent literature on vitamin D is full of controversies regarding its measurement, benefits, diagnosis, and management of its deficiency. In addition to addressing the consequences of deficiency, benefits of its replenishment, and clinical recommendations for supplements, this review addresses extra-skeletal effects of vitamin D. Vitamin D is essential for skeletal health and prevention of falls and injuries. Vitamin D enhances intestinal calcium absorption and mineralization of osteoid tissues. Rickets in children and osteomalacia in adults are classic manifestations of severe vitamin D deficiency. Cohort studies suggest that low 25 hydroxyvitamin D [25(OH)D] affects numerous and diverse physiologic functions, such as control of cell growth including cancer cells, protection against autoimmune disorders, and muscular coordination. Emerging data also suggest that low vitamin D levels may worsen disorders, including cancer, metabolic syndrome, obesity and diabetes, infectious diseases, and autoimmune disorders. Whether increased incidences of these diseases are consequences of widespread vitamin D deficiency is to be determined. Moreover, many reported relationships between vitamin D deficiency and diseases are based on epidemiological observations. Measurement of serum 25(OH)D is the way to evaluate vitamin D status. Serum 25(OH)D levels below 20 ng/mL are considered deficient, whereas optimum levels are between 30 and 50 ng/mL. An additional 1,000 IU of vitamin D per day generally is sufficient for lighter-skinned individuals; elderly, obese, and dark-skinned individuals and other groups of patients may need an additional 2,000 IU or more per day to maintain physiologic serum 25(OH)D levels.
Introduction
The definition of vitamin D deficiency, how and in whom to measure 25-hydroxyvitamin D [25(OH)D], and optimal approaches to vitamin D repletion are topics of controversy. Emerging evidence indicates that vitamin D deficiency may be pandemic (1, 2) . Vitamin D deficiency (serum levels less than 20 ng/mL) is the most underdiagnosed and perhaps the most common medical condition in the world. It is estimated that about 1.8 billion people worldwide have vitamin D deficiency (3) (4) (5) (6) . Deficiency and insufficiency (i.e., those with serum vitamin D levels less than 30 ng/mL) are estimated to occur in approximately 3.2 billion, about half of the world's population.
Vitamin D plays important functions in many tissues, including intestinal absorption of calcium and skeletal development, maintenance, and mineralization. Vitamin D deficiency causes rickets in children and osteomalacia, muscle weakness and falls, osteoporosis, and fractures in adults. Key causes of vitamin D deficiency include less sun exposure, climatic changes, atmospheric pollution (7) , lifestyle changes, obesity, and changes in dietetic patterns. Sensible exposure to sunlight and a better intake of dietary and supplemental vitamin D can prevent this deficiency.
The major function of vitamin D is to regulate the provision of adequate calcium and phosphorus to the body to maintain optimal metabolic functions. In addition, vitamin D has profound effects on the immune system (8), pancreas (9), brain (10), and muscle (3, 11) . It plays an important role in combating infections such as mycobacterium tuberculosis; viral infections, including influenza (12,13); inflammatory bowel disease (14); preventing muscle weakness and falls and fractures (15); improving fertility and reproductive success (16); and preventing cardiovascular disease, depression, insulin resistance, and certain cancers (17). Direct effects of vitamin D in controlling the cell cycle may be one of the key mechanisms of reduction of cancers (18). Moreover, data suggest that sufficient blood concentrations of vitamin D may reduce excess deaths associated with heart disease (19-20); breast, colon, and prostate cancer (21-22); strokes secondary to hypertension (23); and autoimmune conditions (8). However, most of these data are based on cross-sectional and observational studies and may have confounders, such as drug interactions, sunlight exposure,
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Prevalence of vitamin D deficiency
A comparison of the National Health and Nutrition Examination Survey (NHANES) 1988 (NHANES) -1994 (NHANES) and 2001 (NHANES) -2004 databases revealed that the average serum 25(OH)D levels have declined in the United States population. It is likely to be the case in some other countries as well. In the United States, in both genders the prevalence of serum 25(OH)D levels of above 30 ng/mL decreased from 45% to 23% across all ethnic and age groups (1) . There is controversy regarding whether declining vitamin D levels are caused by changes in assay methods or standards (24-26), escalating incidence of obesity, or a true decrease in serum vitamin D levels (6) . Studies have reported more than 50% of North American women receiving antiosteoporosis therapies (27) and 88% of women with fractures have serum 25 (OH)D levels below 20 ng/mL (28). Low serum vitamin D levels have a negative effect on the skeleton, being associated with lower bone mineral density (BMD), increased bone turnover, and increased serum parathyroid hormone (PTH) levels, especially when serum 25(OH)D concentrations are less than 20 ng/mL (29-30).
Vitamin D physiology

Types of vitamin D
There are two forms of vitamin D. Ergocalciferol (vitamin D 2 ) is a plant product. For commercial purposes it is produced by irradiation of yeast or plant sterol ergosterols. Its circulatory half-life is about 8 to 12 days (31). Cholecalciferol (vitamin D 3 ) is animal-derived, synthesized in the skin, and has a half-life of approximately 25 to 30 days.
Studies have reported that administration of 50,000 IU of D 2 or D 3 produced similar increases in the serum concentration of vitamin D (32). Although both agents produced a similar initial increase in serum 25(OH)D levels, the D 3 -treated subjects had additional increases, peaking at day 14 (33). However, when the two forms are administered daily or weekly, equal serum 25(OH)D levels are achieved (34), and thus are considered by some as equivalent (34-35). However, several other studies have reported higher potency of vitamin D 3 compared with D 2 (33,36). Intermittent administration regimens have shown cholecalciferol (D 3 ) to be twice as potent as ergocalciferol (D 2 ) in elevating serum 25 (OH)D and modulating serum PTH levels (31). In light of the half-life differences, it seems logical to use D 3 when supplementing at longer intervals. Vitamin D 3 has become the gold standard for vitamin D supplementation (6) .
Generation of vitamin D
The synthesis of cholecalciferol, the "sunshine vitamin", starts with the conversion of 7-dehydrocholesterol (7-DHC) to previtamin D upon photolytic, nonenzymatic reaction after skin exposure to solar ultraviolet-B rays (3) . In the skin, this pre-vitamin D 3 isomerizes to vitamin D 3 , which has a several-fold higher affinity to the vitamin D-binding protein (DBP), and thus is preferentially transported via the bloodstream from the skin to the liver. In liver parenchymal cells, cytochrome (CYP) P450 enzyme converts it to 25 (OH)D in a substrate-dependent manner. Circulatory 25 (OH)D is bound to DBP and albumin. In a highly regulated process in the proximal renal tubular epithelia, 25 (OH)D is converted to active vitamin D, 1,25hydroxyvitamin D 3 [1,25 (OH) 2 D] via C 1 -hydroxylation by mitochondrial hydroxylase CYP27B1. This enzyme is stimulated by PTH and inhibited by calcium, phosphorus, and fibroblast growth factor-23 (FGF-23). FGF-23 is primarily produced by osteocytes and osteoblasts. 1,25 (OH) 2 D stimulate FGF production (37). Under or overproduction of FGF-23 affects vitamin D metabolism and phosphate handling. For example, in patients with chronic kidney disease with elevated FGF-23 contributes to renal bone disease and osteomalacia. The serum level of 1,25 (OH) 2 D is approximately 1,000fold less than that of 25 (OH)D, but active vitamin D has a 1,000-fold higher affinity to the vitamin D receptor (VDR). Figure 1 shows the pathway of generation of 25 (OH)D and 25(OH) 2 D in humans.
Interactions of PTH with PTH/PTH-related peptide receptors in the renal tubular epithelial cell membranes increase 1α-hydroxylase (CYP27B1) enzyme activity. Once the serum calcium is normalized, 1α-hydroxylase enzyme, and thus the PTH-1α-hydroxylase axis, is down-regulated. On the other hand, the FGF-23 activates 24-hydroxylase enzyme (38), thus diverting the conversion of vitamin D to a metabolically inactive form, 24,25(OH) 2 D. 1α-hydroxylase enzyme is also present in extra-renal cells, including keratinocytes, monocytes, macrophages, and T-and Blymphocytes. However, 1α-hydroxylase enzyme in these cells is not regulated by serum calcium. modulates the expression of vitamin D-dependent genes. Ligand binding to the VDR induces its conformational changes and heterodimerization with the retinoid X receptor (9). 1,25(OH) 2 D also elicits non-genotropic effects (39, 41), including rapid activation of protein kinases and modulation of the electrical state of cells. Abnormalities in the VDR or the inability to activate the VDR in the absence of adequate amounts of 1,25(OH) 2 D lead to manifestations of clinical signs and symptoms of vitamin D deficiency.
Data suggest that PTH-mediated bone resorption may require calcium-stimulated, calcium-sensing receptor (CaSR)-mediated osteoclastic activity (42). This suggests interactions of CaSR, vitamin D, and 1α-hydroxylase, modulating bone turnover and skeletal growth. Vitamin D stimulates osteoblast and stromal cell production of receptor activator of nuclear factor kappa-B ligand (RANK-L), a key regulator of osteoclast recruitment and differentiation (43).
Diagnosis of vitamin D deficiency
Worldwide, immunological methods are widely used to measure serum vitamin D levels, but liquid chromatography tandem mass-spectrometric assays (LS/MS/MS) are thought to be the most consistent way of measuring vitamin D (44-45). Although the normal serum levels remain a matter of controversy, the diagnosis of vitamin D deficiency usually is confirmed when the measured serum 25(OH)D levels are below 20 ng/mL (50 nmol/L) (Table 1 ) (30,46). A serum 25(OH)D level of between 20 and 30 ng/ mL (50-75 nmol/L) is considered deficient (6), whereas levels below 10 ng/mL (≤25 nmol/L) may be associated with signs and symptoms and are considered severe vitamin D deficiency (47-48).
Vitamin D deficiency leads to secondary hyperparathyroidism, stimulation of renal tubular 1α-hydroxylase activity, and increased production of 1,25(OH) 2 D. Consequently, only at very low levels of 25(OH)D do serum 1,25(OH) 2 D levels begin to decline. Thus, measurement of the 1,25(OH) 2 D level should not be used as a marker in the diagnosis of vitamin D deficiency (49).
Serum vitamin D levels below which secondary hyperparathyroidism appear are not agreed upon (50-52). Most studies reported that a 25(OH)D level below 20 ng/mL is associated with adverse skeletal effects (52-53), but others refute this (54-55). Nevertheless, vitamin D supplementation alleviates secondary hyperpara-thyroidism, increases BMD (56), improves muscle function and reduces falls (57) , and reduces hip and other osteoporotic fractures (54-55). Consequently, many endocrinologists prefer their patients maintain serum vitamin D levels between 30 and 50 ng/mL (75-125 nmol/L) (35, 58, 59) .
Vitamin D receptor
The vitamin D receptor (VDR) is a member of the super family of nuclear hormone receptors located in the cell nuclei and widely distributed in tissues. Classical functions of 1,25(OH) 2 D, such as calcium metabolism, antiproliferative effects, and immuno modulatory activities are mediated through the VDR (39-40). 1,25(OH) 2 D and VDR interactions modulate a large number of genes that lead to the vitamin's biological actions (40). 1,25(OH) 2 D 3 is the high-affinity ligand for the VDR in key target tissues that 
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Healthy blood levels of vitamin D
Most reports indicate that the minimum desirable serum 25(OH)D level is between 28 and 32 ng/mL (70-80 nmol/L) (46, 58), but not everyone agrees with this (52). Moreover, these cut-off points may not necessarily apply to all, especially to vulnerable population groups. The 2010 Institute of Medicine (IOM) report on vitamin D suggests 20 ng/mL is adequate for health (52), but most other studies indicate that at least 30 ng/mL is necessary (1, 60) . In fact, even higher levels have been suggested (35, 59) . Recent data from two sub-Saharan tribes with dark skin who do not use sunscreen and wear little clothing reported to have mean serum 25(OH)D level of 46 ng/mL (115 nmol/L) (61) .
Extra-skeletal disorders, such as autoimmune diseases, obesity, type 2 diabetes, and cancer prevention, may require a higher level of serum vitamin D (48-49,62).
Institute of Medicine (IOM) 2010 report on vitamin D
The IOM report (52) used a population model based on a healthy North American population. The American Endocrine Society recommendations (35,52) are directed at patients (6) . IOM recommendation that same dose (600 IU) of vitamin D is adequate across the spectrum of ages, from one-year old and 70-year old is puzzling. Both the IOM and the Endocrine Society reports recommend increasing the safe intake of vitamin D to 4,000 IU/day (35, 52) . Serum levels of vitamin D as high as 60 ng/mL are safe, but the long-term safety of levels higher than 60 ng/ mL has not been established (48). Nevertheless, some population-based cross-sectional studies, such as NHANES, give some indication of increased all-cause mortality with high serum levels of vitamin D (63-64). However, many other studies report that the higher the serum 25(OH)D level, the lower the morbidity associated with several non-communicable diseases (65) (66) (67) (68) .
American Endocrine Society Guidelines
The American Endocrine Society guidelines recommend a minimum serum vitamin D level of 30 ng/mL, but to achieve sufficiency, the guidelines suggest aiming for levels between 40 and 60 ng/mL (35). The report states that in individuals who are not at risk, there is no good evidence for population-based screening for vitamin D deficiency. The report also states that vitamin D 2 and vitamin D 3 are equally satisfactory in treating and preventing vitamin D deficiency (35).
The guidelines recommend two-to three-fold higher doses of vitamin D for obese patients and those who are taking anticonvulsants, glucocorticoids, antifungals, or medications for AIDS. Guideline increased the tolerable upper limit for vitamin D in healthy adults to ~4,000 IU per day and the safe upper limit to 10,000 IU a day (35). The guidelines confirmed the benefits of vitamin D supplementation in fall prevention. However, due to the lack of data from randomized controlled trials (RCT), administering higher-than-recommended amounts of vitamin D to prevent cancer, cardiovascular, or other diseases or to improve quality of life was not recommended (35). 
Risk factors for development of vitamin D deficiency
Asian Indians who immigrate to northern Europe have lower serum 25(OH)D levels and a higher incidence of rickets and osteomalacia than do whites (69) . In addition to containing little vitamin D, vegetarian diets contain high amounts of phytic acid and fibre, which reduces intestinal calcium and vitamin D absorption. Consequently, in the absence of adequate exposure to sunshine or supplementation, those who consume such diets, particularly vegans, could become vitamin D deficient and malabsorb calcium. Consequently, irrespective of the age, it would be useful to give 2,000 IU/day of vitamin D to vegans (6) . Vitamin D deficiency is highly prevalent among the elderly and institutionalized persons (54,70). In part this is due to insufficient exposure to sunlight; being homebound, institutionalized, or non-ambulatory; avoiding sunlight exposure; an inability to generate vitamin D in the skin; and consumption of certain medications such as anticonvulsants, glucocorticoids, and any medication that enhances the catabolism of vitamin D (71) ( Table 2) .
Other groups of patients who are vulnerable to vitamin D deficiency include those with gastrointestinal diseases (e.g., celiac disease, malabsorption syndromes), obesity, and disabilities (71, 72) . Those who have had rapid weight loss, such as after dieting or bariatric surgery, are particularly vulnerable; they require higher doses of vitamin D (73) .
Manifestation of vitamin D deficiency
People with prolonged, severe vitamin D deficiency are likely to present with various clinical signs and symptoms of osteomalacia, such as proximal myopathy, pseudo-fractures, and biochemical evidence of raised bone-specific alkaline phosphates (6) . Additional symptoms attributable to vitamin D deficiency include lethargy, increased incidence and severity of infections, and exacerbation of chronic non-communicable diseases, immunological disorders including rheumatoid arthritis and multiple sclerosis, and musculo-skeletal issues such as low backache and bone pain, muscle aches, and inability to lose weight (74) .
Improving vitamin D status is a highly cost-effective, modifiable risk factor for reducing falls and fractures (75, 76) . Except for an isolated or poorly designed study, most clinical studies have reported a positive effect of vitamin D supplementation on falls and fracture reduction. In one study, 500,000 IU of cholecalciferol was administered annually, with a slight increase in falls and fractures recorded in the treated group (77) . However, the mean serum 25(OH)D levels achieved in the vitamin D-treated group were below 30 ng/mL for at least 6 months of the year. There is a large fluctuation of the post-dosing peak and the end-of-the-year trough of serum 25(OH)D levels. Such levels and rapid changes are unphysiological and may be harmful (78, 79) . Moreover, vitamin D supple- mentation is known to improve well-being, so those who are treated are likely to increase their activities, leading to a higher incidence of falls and injuries. Considering the overall picture, despite the data presented, the interpretation that a high-dose vitamin D regimen increases falls may not be correct (77) . In addition to causes, there are a number of common lifestyle issues that have led to the current global epidemic of vitamin D deficiency. Table  3 summarizes these.
weakness (82) (83) (84) (85) (86) (87) . Moreover, serum vitamin D levels below 20 ng/mL (50 nmol/L) are associated with increased body sway and decreased muscle strength (15) and significant increased risk for falls (88) . Clinical studies that used more than 800 IU vitamin D supplementation, with or without calcium, has shown improvement in muscle strength and balance (75, 89) and physical performance.
The exact mechanism of action in neuromuscular coordination and the fall reduction with vitamin D supplementation needs additional studies, but improvements in muscle functions, balance, mobility, and reflexes have been implicated (15, 81, 90) . Taking these data together, it is rational and cost-effective to initiate programs for routine vitamin D supplementation for residents in nursing homes, long-term care facilities, and developmental disability centres, and also for most elders even without measurement of serum 25(OH)D levels.
Vitamin D, balance, and fall risk reduction
Many studies have reported that vitamin D supplementation significantly reduces falls (55, 76, 91, 92) . Approximately 30% of individuals older than 65 years fall at least once each year; approximately 0.5% of these falls result in a fracture. Frequency of falls increases with age, and falls lead to injuries and death (93) , especially in those with low serum 25(OH)D levels (94) . Thus, fall and injury prevention should be a key component of managing these vulnerable patients and our elderly population.
In a residential set-up, the number of patients needed to be treated with vitamin D to prevent major fractures is about 25 patients per year (6) . Management of a hip fracture costs on average $40,000, whereas the cost of vitamin D therapy for a patient per year is approximately $10. Thus, no intervention is more cost effective in these patient populations than the provision of adequate vitamin D supplements.
Several meta-analyses reported that vitamin D supplementation significantly improves mobility and reduces the risk of falls (57, 88) in the ambulatory elderly (76, 81, 88) and among institutionalized elderly (88, 90) . Nevertheless, one needs to be cautious in drawing conclusions from some of these meta-analyses because the same sets of data have been used repeatedly (54-55, [75] [76] [95] [96] [97] [98] [99] [100] [101] . It is also noteworthy that some studies have reported no correlations between vitamin D supplementation and reduction of falls (77, 102) .
A meta-analysis of eight randomized trials involving 2,426 older patients demonstrated that daily treatment with between 700 and 1,000 IU of vitamin D lowered the risk for falling by 19% (95) . Another meta-analysis has reported 46% reduction of falls after dietary calcium and vitamin D supplementation in ambulatory older women and 65% reduction in less active women (103) . Thus, improving vitamin D status is an important modifiable risk factor for reducing falls and fractures. However, because the halflife of vitamin D is in days, administration of vitamin D at 
Vitamin D, muscle function, and falls
Vitamin D is necessary for calcium transport and the actin-myosin interaction (80) . Vitamin D receptors are present on the fast-twitch muscle fibres, which are the first to respond in a fall. Lower serum 25(OH)D levels are associated not only with sarcopenia and proximal muscle weakness, but also with loss of type II muscle fibres (81) . Those with 25(OH)D levels less than 10 ng/mL (25 nmol/ L) are twice as likely to have sarcopenia and muscle Vol.2, No.2, August 2012 Vitamin D and clinical care intervals of more than a month or two, is unlikely to be effective and should not be practised.
Muscle weakness and muscular incoordination may be the most important risk factors for falls and consequent fractures that can be corrected with vitamin D supplements (6) . Vitamin D supplementation is an inexpensive, welltolerated, and cost-effective strategy for reducing falls and injuries in older adults and should be incorporated into the clinical practice by those who provide care for the elderly. Nevertheless, to make the treatment effective, attention should be given to other factors contributing to falls, including correction of vision and hearing, improving home safety, and minimizing environmental hazards and so forth that leads to falls. Thus, all osteoporosis and fracture-prevention programs should incorporate these.
Vitamin D and skeletal health
Vitamin D is necessary for the bone mineralization and skeletal health (104); thus, vitamin D deficiency could lead to osteomalacia and also contribute to osteoporosis. Vitamin D deficiency is also associated with reduced calcium absorption (105), bone loss (106), increased bone turnover (71, 72) , osteoporosis (107) , and increased risk of falls and fracture (108, 109) . Moreover, in the absence of adequate intakes of calcium and vitamin D, none of the potent anti-osteoporosis medications would work; in fact they can be harmful.
Although osteoporosis and osteomalacia can coexist, especially in vulnerable populations such as institutionalized patients with high incidence of vitamin D deficiency, low BMD as measured by dual energy x-ray absorptiometry (DXA) is often only considered as osteoporosis (48). Thus, osteoporosis treatment focuses primarily on anti-osteoporosis therapy, instead of offering inexpensive and effective solutions, such as healthy lifestyle changes, weight-bearing exercises, and calcium and vitamin D supplements. Calcium and vitamin D therapy in such patients could significantly increase their BMD (60) and also prevent fractures (48). The current data suggest that the threshold levels of 1,25(OH) 2 D necessary for beneficial non-skeletal effects seem to be higher than that required for stimulation of intestinal absorption of calcium and release of calcium from bone (110, 111) .
Vitamin D and fractures
Several epidemiologic studies have reported inverse associations between serum vitamin D levels and fractures (112) . Studies also reported that vitamin D sufficiency is associated with a low incidence of fractures (55). The Women's Health Initiative study suggested that every 10-ng/mL decrease in serum vitamin D levels doubles the risk of hip fractures, especially when the levels are below 30 ng/mL (109) .W A meta-analysis that consisted of five RCTs (n=9,294) of hip fractures and seven RCTs (n=9,820) of non-vertebral fractures with oral vitamin D, with or without calcium, also reported a significant reduction of fractures (55). Vitamin D doses in excess of 700 to 800 IU/day reduced the risk of hip and non-vertebral fractures by 26% compared with calcium alone or placebo, whereas 400 IU/day failed to prevent fractures (Medline and Cochrane Controlled Register and EMBASE [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] ) (55). Although some studies have suggested that the threshold for fracture reduction is approximately 20 ng/ml (113) (114) , other studies reported a lack of effect of calcium and vitamin D on fracture reduction (115) (116) (117) (118) (119) (120) (121) . Nevertheless, these studies have used less-than-optimum doses of supplementary vitamin D (on average, 400 IU/day), had small sample size, were of shorter duration, and/or administered the vitamin too infrequently (77, 117, 122) .
A Cochrane review reported that vitamin D 3 reduced hip fractures but may not reduce other fractures (99); the reason is unclear. Analysis of eight clinical trials revealed a significant reduction in hip fractures in those who received both vitamin D and calcium. Overall, the Cochrane review suggests higher doses of vitamin D are more effective and the provision of calcium with vitamin D could be helpful. Most studies have examined the relationship between the supplemented vitamin D doses and falls and fractures (88, 93, 96, 99) . Only a few studies have examined the relationships between serum levels of vitamin D needed or achieved and the reduction in falls or factures (96, 100, 101) ; more such RCT studies are needed.
Sources of vitamin D
Vitamin D from sunlight: To produce enough vitamin D, a fair-skinned person needs an exposure of 25% of the body surface to sunlight for approximately 15 to 20 minutes, four to six times a week. After sun exposure, the peak serum 25(OH)D 3 level is reached in about 7 to 14 days, but the mean levels achieved in individuals are highly variable (6) .
Calcium and vitamin D from the diet:
High quantities of vitamin D are found naturally only in a few foods, including fatty fish and irradiated mushrooms (6) . In some countries, certain foods, such as milk, yogurt, orange juice, margarine, infant formula, and breakfast cereals, are fortified with vitamin D. Some calcium supplements and multivitamins also contain small amounts of vitamin D. Most generic multivitamin tablets contain between 200 and 400 IU of vitamin D and 200 to 600 mg of calcium. However, the recent preparations of multivitamins contain 1,000 IU of vitamin D 3 . For most patients, calcium supplementation of more than 500 to 800 mg a day is not necessary (i.e., total daily calcium intake [diet + supplements] is recommended to be less than 1,500 mg) (http://www.asbmr.org).
Guidance for vitamin D supplementation
Measurement of serum 25(OH)D levels provides the diagnosis of vitamin D deficiency, but additional information, such as renal function, serum calcium, and PTH, is helpful for understanding the deficiency. The measurement of 24-hour urine calcium is also helpful in identifying calcium conservation or wasting status that is associated with hypovitaminosis D or hypercalcemia. The use of artificial ultraviolet-B irradiation and lamps to increase serum vitamin D levels has been explored in short-term studies (123) (124) (125) , but the long-term safety of such therapies is not established.
Children, pregnant women, institutionalized patients, obese patients and those who have experienced rapid weight loss, gastric bypass patients, those taking antiepileptic drugs, those living in northern latitudes during winter months, people with darker skin who live in northern latitudes, and those who avoid sunlight should be considered for vitamin D supplementation (3, 48 ). An intermediate group at high risk that also should be treated with vitamin D includes patients with celiac disease, inflammatory bowel syndrome, cystic fibrosis, recurrent infections, chronic liver and kidney disease, and those receiving antiretroviral or long-term glucocorticoid therapy (6, 48) .
A peak serum 25(OH)D level is achieved between 2 and 3 days after an oral dose of 50,000 IU of vitamin D. The treatment goal is to achieve serum 25(OH)D levels above 30 ng/mL. Recent reports recommend keeping the serum vitamin D levels between 30 and 40 ng/mL (30, 35, 59) . Most patients with vitamin D deficiency require therapeutic doses of vitamin D given over several weeks to bring their serum vitamin D levels above 30 ng/mL, followed with maintenance doses between 1,000 and 2,000 IU a day. Thus, where facilities are available, it is recommended to measure serum 25(OH)D levels approximately 3 to 4 months after the therapeutic course of vitamin D supplementation to assess the adequacy and necessity of additional interventions.
Vitamin D deficiency in primary hyperparathyroidism
Vitamin D deficiency occurs more frequently in patients with primary hyperparathyroidism (PHPT) than in the general population (126) (127) (128) (129) (130) (131) . Primary hyperparathyroidism should be considered in patients who do not normalize serum PTH levels after correction of vitamin D deficiency (126) ; however, in some patients, these two disorders may co-exist (132) . Therefore, the measurement of serum 25(OH)D levels is essential in all hyperparathyroid patients. Some patients with secondary hyperparathyroidism may take 4 to 6 months to normalize serum PTH levels. Approximately 65% of patients with PHPT have serum vitamin D levels below 25 ng/mL (126) (127) (128) (130) (131) . In many of these patients, serum PTH levels will decrease once the vitamin D deficiency is corrected, especially in those with secondary hyperparathyroidism (130) , whereas in others it may take a few months to achieve (6) .
The current practice and the recommendations of vitamin D supplementation for PHPT are based on the following: (1) high prevalence of vitamin D deficiency in patients with PHPT; (2) vitamin D inadequacy worsens the clinical picture of PHPT; (3) in some patients with PHPT, vitamin D deficiency can mask hypercalcemia and thus obscure the diagnosis; and (4) in patients with PHPT and vitamin D deficiency, vitamin D replacement is safe and only rarely increases serum calcium levels (6) .
Normalization of vitamin D in hyperparathyroidism
In patients with PHPT, it is advisable to treat vitamin D insufficiency cautiously to avoid hypercalcemia (133, 134) , especially in patients with markedly elevated serum calcium levels because vitamin D therapy may worsen hypercalcemia. In patients with PHPT, the goal is to maintain serum vitamin D levels around 25 ng/mL (62 nmol/L) (6) . Replacement therapy is discontinued or the dose is lowered once the serum vitamin D level reaches the target level. To prevent exacerbation of hypercalcemia and hyper-calciuria, monitoring of serum and urine calcium levels in PHPT patients receiving vitamin D therapy is suggested (132, (135) (136) (137) (138) . In most patients with PHPT, although serum PTH may decrease a bit, there are no significant increases in serum calcium levels after normalization of serum vitamin D.
It is relatively common to find high serum PTH levels with normal or low-normal serum calcium levels in patients with osteoporosis (132, (135) (136) (137) (138) (139) (140) . In this setting, measurement and appropriate replacement of vitamin D (132) facilitate making the right diagnosis: (A) Secondary hyperparathyroidism: PTH values will return to the normal range with replenishment of vitamin D, whereas calcium levels remain within the normal limits (141); (B) Concomitant PHPT and vitamin D deficiency: PHPT-associated hypercalcemia may be masked by co-existing vitamin D deficiency. Thus, vitamin D supplementation may uncover biochemical hypercalcemia with persistent elevation of serum PTH levels (126) ; or (C) Normocalcemic hyperparathyroidism, characterized by high serum PTH but normal plasma calcium in the presence of normal serum vitamin D levels (135, 141) .
Extra skeletal effects of vitamin D
Vitamin D has beneficial effects on a variety of tissues and in disorders. Recent epidemiological and observational studies and data from in vitro and in vivo animal studies reveal that vitamin D has a wide range of physiological actions. However, many conditions that are aggravated by vitamin D deficiency unfortunately are labelled as "age-related" morbidities and thus go undiagnosed. These include sarcopenia, falls, overactive bladder, swallowing dysfunction, decreased lung function, macular degeneration, and decline in cognitive functions (6) .
Properly designed randomized studies in the future could clarify cause-and-effect relationships of low vitamin Vol.2, No.2, August 2012
Vitamin D and clinical care
D with health problems such as muscle weakness, cancer, autoimmune disease, diabetes, schizophrenia, depression, premenstrual syndrome, lung dysfunction, kidney disease, preeclamptic toxaemia, and cardiovascular disease. Data also suggest that adequate vitamin D prolongs lifespan (142, 143) , especially in patients with chronic renal disease (CKD) (144) (145) (146) . The IOM report suggests an increase of mortality in those with serum vitamin D levels above 50 ng/mL, but this conclusion was based on a handful of observational reports. On the contrary, overall data support association between lower serum vitamin D and increased all-cause mortality (143, 147, 148) .
Vitamin D deficiency may also aggravate a host of clinical conditions that impair the health of the individual, including increased susceptibility to bacterial and viral infections, osteoporosis, increased risk of falls and fractures, increased risk of cancers, hypertension, cardiovascular disease, obesity, type 2 diabetes, oral and gum disease, and autoimmune diseases. Figure 3 illustrates complex interactions between vitamin D and various organ systems.
(2.5 nmol/L) decrement of 25 (OH)D below 30 ng/mL. The latter regimen without the administration of therapeutic doses likely will take several months to normalize serum vitamin D levels.
In most patients who are younger than 65 years, serum vitamin D levels can be maintained in the normal range using 1,000 IU/day. However, for those older than 65 years, higher doses such as 2,000 IU a day or 10,000 IU once or twice a week, or 50,000 IU of vitamin D 3 once a month may be required (149) . In the absence of a maintenance dose, serum vitamin D levels will revert to their baseline levels in most patients within months. Certain at-risk individuals, including those who are obese, have had bariatric surgery, have malabsorption syndromes, or are taking medications that affect vitamin D catabolism, should be given higherthan-usually-accepted doses, followed by a higher maintenance doses of 3,000 to 5,000 IU per day or 50,000 IU several times a month (35).
Safety and adverse effects
Because of depletion of vitamin D stores in the body, low-dose daily regimens generally take several months to normalize serum vitamin D levels. However, the use of upfront loading doses or therapeutic doses such as 50,000 IU once or twice a week for a few weeks will bring the serum 25 (OH)D levels to the normal range within weeks, and the patients have early symptomatic improvements. When considering deficits of vitamin D that are in the range of 1 million IU or more in a given patient, there is no reason to be apprehensive about prescribing therapeutic doses of non-activated parental vitamin D for short periods.
Some studies have shown vitamin D dosages as high as 10,000 IU daily (150) for 6 months are safe (79, 150) . Acute signs and symptoms of vitamin D toxicity mirror those of hypercalcemia: headache, irritability, metallic taste, nephrocalcinosis, vascular calcinosis, renal impairments, pancreatitis, dehydration, nausea, and vomiting. Because of the potential for the development of hypercalcemia and hypercalciuria, vitamin D supplementation should be used cautiously in patients with PHPT, granulomatous diseases, metastatic bone disease, sarcoidosis, and Williams' syndrome (30,151).
Compared to vitamin D, its metabolites are much expensive and associated with greater than 5,000-fold higher incidence of adverse effects. Thus, there is no rational in prescribing any activated forms of vitamin in D or its metabolites, including 1α products or 1,25 (OH) 2 D (calcitriol) for patients with osteoporosis. These agents should be reserved for the management of patients with (A) chronic kidney disease and (B) hypoparathyroidism, to maintain their serum calcium at physiological levels. However, there are independent beneficial effects of vitamin D and 1α hydroxylated metabolites including 1,25 
Vitamin D supplementation
Following are three easy and practical regimens of administering therapeutic doses of vitamin D: (A) When the serum vitamin D level is below 10 ng/mL, administer 50,000 IU three times a week; for a serum level between 11 and 20 ng/mL, administer 50,000 IU twice a week; and for a serum level between 21 and 29 ng/mL, administer 50,000 IU once a week, for eight weeks. (B) Administer a varying single loading dose of vitamin D (e.g., 300,000), followed by 50,000 IU once or twice a week until serum vitamin D levels increase above 30 ng/mL. (C) Administer an extra 100 IU of vitamin D daily for each nanogram per millilitre Clinical update (OH) 2 D in the body. Therefore, to maintain optimal health, patients with chronic kidney disease require both parental vitamin D (any over the counter preparation) and activated vitamin D, 1,25(OH) 2 D at appropriate doses. Figure 4 illustrates the activation of the natural and synthetic forms of vitamin D. Although the excitement over the positive health benefits of vitamin D seems warranted, caution has been urged, in part because of inadequate RCTs. Meanwhile, only a few small clinical trials reported to date used different doses of vitamin D, correlated any outcome associated with the serum vitamin D levels achieved, or attempted to correlate such valuable data with skeletal and extra-skeletal diseases. Nevertheless, available data and observations to date strongly support the role of vitamin D in promoting a variety of health indices, prevention of falls, and good skeletal health (3, (152) (153) .
Conclusions
Vitamin D plays a critical role in skeletal health, and its deficiency is associated with increased falls and fractures. In addition to regulating number of clinically important genes and calcium and phosphate homeostasis, vitamin D is involved in the regulation of immunity and cell growth and influences a wide array of common diseases, including cancers, cardiovascular disease, autoimmune conditions, and infections. Hypothesesdriven, adequately powered, well-designed, outcomebased, dose-ranging randomized controlled clinical trials leading to firm conclusions are necessary. Recycling data with multiple meta-analyses will not advance the vitamin D field. Overall data support that the use of recommended doses of vitamin D is highly cost-effective with no adverse effects. Thus, good quality vitamin D 3 supplements (but not active vitamin D metabolites) should be offered to our patients.
Recommendations
Sunlight exposure often is limited by lifestyle, but obtaining enough vitamin D from the diet alone is difficult. Thus, many adults require vitamin D supplementation, generally between 1,000 and 2,000 IU a day. The IOM report was aimed at public health use and the conclusions made are based on healthy individuals and thus are not applicable to patients (52). The IOM recommendations should not be considered for patient care, whereas the American Endocrine Society recommendations are clinically relevant (35).
The introduction of a national policy to routinely supplement adequate amounts of vitamin D to vulnerable populations, such as those with CKD and those living in nursing homes or disability centres, would reduce falls and fractures, and decrease morbidities and deaths with a minimal cost. Considering the variability of assays and the cost of measurement of serum vitamin D, the high safety margin of supplementation, and the high incidence of vitamin D deficiency, it is rational to recommend routinely supplementing these vulnerable groups with 50,000 IU vitamin D 3 once or twice a month. This would cost approximately $10 to $15 per patient per year. Supplementing once or twice a month is also more economical and practical than giving daily supplements. Even if this regimen reduces at least one fracture per institution per year, it is would be cost-effective. 
